{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:02Z","timestamp":1790797082467,"version":"4.1.0"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1093\/mmy\/myy052","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T12:03:17Z","timestamp":1530100997000},"page":"S168-S178","source":"Crossref","is-referenced-by-count":68,"title":["Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?"],"prefix":"10.1093","volume":"57","author":[{"given":"Jeffrey D","family":"Jenks","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California\u2013San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay R","family":"Mehta","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California\u2013San Diego, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California\u2013San Diego, San Diego, California, USA"},{"name":"Section of Infectious Diseases and Tropical Medicine AND Division of Pulmonology, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"key\n\t\t\t\t2019022811005785800_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/myc.12628","article-title":"Improving outcome of fungal diseases: guiding experts and patients towards excellence","volume":"60","author":"Cornely","year":"2017","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019022811005785800_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6515-1_2","article-title":"The changing epidemiology of invasive fungal infections","volume":"1508","author":"Enoch","year":"2017","journal-title":"Methods Mol Biol"},{"key":"key\n\t\t\t\t2019022811005785800_bib3","doi-asserted-by":"crossref","DOI":"10.1159\/000487713","article-title":"Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with pneumocystis jirovecii pneumonia","author":"Salzer","year":"2018","journal-title":"Respiration"},{"key":"key\n\t\t\t\t2019022811005785800_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2018.08.005","article-title":"Rare mold infections caused by Mucorales, Lomentospora prolificans and Fusarium, San Diego: the role of antifungal combination therapy","author":"Jenks","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019022811005785800_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","article-title":"Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/AAC.50.1.286-293.2006","article-title":"Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Schmitt-Hoffmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib7","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume":"71","author":"Lass-Florl","year":"2011","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2019022811005785800_bib8","doi-asserted-by":"crossref","first-page":"e02655","DOI":"10.1128\/AAC.02655-17","article-title":"Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy and tolerability","volume":"62","author":"Lenczuk","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijantimicag.2014.03.013","article-title":"Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies","volume":"44","author":"Hoenigl","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019022811005785800_bib10","article-title":"No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data","author":"Schmitt-Hoffmann","year":"2008"},{"key":"key\n\t\t\t\t2019022811005785800_bib11","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00514-16","article-title":"Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study)","volume":"60","author":"Kovanda","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib13","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib14","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.2174\/13816128113199990342","article-title":"Antifungal therapy of aspergillosis of the central nervous system and Aspergillus endophthalmitis","volume":"19","author":"Hoenigl","year":"2013","journal-title":"Curr Pharm Des"},{"key":"key\n\t\t\t\t2019022811005785800_bib15","article-title":"Isavuonaole is widely distributed in rat tissue","author":"Schmitt-Hoffman","year":"2012"},{"key":"key\n\t\t\t\t2019022811005785800_bib16","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Interactions of azole antifungal drugs with other coadministered agents","volume":"10","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib17","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/DDDT.S145545","article-title":"Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy","volume":"12","author":"Jenks","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"key\n\t\t\t\t2019022811005785800_bib18","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: Pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib19","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1128\/AAC.02942-15","article-title":"Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib21","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cis437","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.00957-06","article-title":"Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods","volume":"51","author":"Pascual","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib25","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1128\/AAC.00389-16","article-title":"Posaconazole plasma concentrations on days three to five predict steady-state levels","volume":"60","author":"Prattes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib26","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijantimicag.2012.02.002","article-title":"Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies","volume":"39","author":"Hoenigl","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019022811005785800_bib27","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1016\/j.ijid.2011.06.004","article-title":"Voriconazole-related severe adverse events: Clinical application of therapeutic drug monitoring in korean patients","volume":"15","author":"Kim","year":"2011","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib28","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1128\/AAC.00637-11","article-title":"Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis","volume":"55","author":"Campoli","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib29","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/infdis\/jit358","article-title":"Pharmacokinetics of posaconazole within epithelial cells and fungi: Insights into potential mechanisms of action during treatment and prophylaxis","volume":"208","author":"Campoli","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Hematologica"},{"key":"key\n\t\t\t\t2019022811005785800_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Executive summary of the 2017 ESCMID-ECMM guideline for the diagnosis and management of aspergillus disease","author":"Ullmann","year":"2018","journal-title":"Clin Microb Infect"},{"key":"key\n\t\t\t\t2019022811005785800_bib32","doi-asserted-by":"crossref","first-page":"E1026","DOI":"10.1073\/pnas.1518836113","article-title":"ImmunoPET\/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo","volume":"113","author":"Rolle","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t2019022811005785800_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/myc.12704","article-title":"Clinical evaluation of the newly formatted lateral-flow device for invasive pulmonary aspergillosis","volume":"61","author":"Hoenigl","year":"2018","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019022811005785800_bib34","first-page":"528","article-title":"Galactomannan testing and aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis","volume":"55","author":"Eigl","year":"2017","journal-title":"Med Mycol"},{"key":"key\n\t\t\t\t2019022811005785800_bib35","doi-asserted-by":"crossref","first-page":"178-015-0905-x","DOI":"10.1186\/s13054-015-0905-x","article-title":"Multicenter evaluation of a lateral-flow device test for diagnosing invasive pulmonary aspergillosis in ICU patients","volume":"19","author":"Eigl","year":"2015","journal-title":"Crit Care"},{"key":"key\n\t\t\t\t2019022811005785800_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/myc.12343","article-title":"Diagnostic accuracy of the aspergillus-specific bronchoalveolar lavage lateral-flow assay in haematological malignancy patients","volume":"58","author":"Prattes","year":"2015","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019022811005785800_bib37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/myc.12757","article-title":"Evaluation of the new AspID polymerase chain reaction assay for detection of Aspergillus species: a pilot study","volume":"61","author":"Prattes","year":"2018","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019022811005785800_bib38","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1634\/theoncologist.2010-0290","article-title":"Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles","volume":"16","author":"Ramos","year":"2011","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t2019022811005785800_bib39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J Infect"},{"key":"key\n\t\t\t\t2019022811005785800_bib40","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/myc.12081","article-title":"Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study","volume":"56","author":"Lewis","year":"2013","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019022811005785800_bib41","article-title":"European health information gateway: autopsy rate for hospital deaths","year":"2018"},{"key":"key\n\t\t\t\t2019022811005785800_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t2019022811005785800_bib43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2011.051995","article-title":"Comparative clinical effectiveness of prophylactic voriconazole\/posaconazole to fluconazole\/itraconazole in patients with acute myeloid leukemia\/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period","volume":"97","author":"Ananda-Rajah","year":"2012","journal-title":"Haematologica"},{"key":"key\n\t\t\t\t2019022811005785800_bib44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022811005785800_bib45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022811005785800_bib46","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019022811005785800_bib47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2019022811005785800_bib48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s15010-013-0562-4","article-title":"Antifungal prophylaxis following allogeneic haematopoietic stem cell transplantation: what is the role of voriconazole","volume":"42","author":"Hoenigl","year":"2014","journal-title":"Infection"},{"key":"key\n\t\t\t\t2019022811005785800_bib49","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.bbmt.2016.09.019","article-title":"Long-lasting protective effect of posaconazole prophylaxis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Busca","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t2019022811005785800_bib50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejcsup.2007.06.006","article-title":"Primary antifungal prophylaxis in leukaemia patients","volume":"5","author":"Maertens","year":"2007","journal-title":"EJC Supplements"},{"key":"key\n\t\t\t\t2019022811005785800_bib51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/myc.12727","article-title":"Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: an illustrative case study","volume":"61","author":"Hoenigl","year":"2018","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019022811005785800_bib53","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/cid\/ciu673","article-title":"Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis","volume":"59","author":"Duarte","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib54","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/myc.12679","article-title":"Levels of interleukin (IL)-6 and IL-8 are elevated in serum and bronchoalveolar lavage fluid of haematological patients with invasive pulmonary aspergillosis","volume":"60","author":"Heldt","year":"2017","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019022811005785800_bib55","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijantimicag.2015.05.017","article-title":"Influence of mould-active antifungal treatment on the performance of the aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test","volume":"46","author":"Eigl","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t2019022811005785800_bib56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cmi.2015.09.009","article-title":"Prospective multicentre PCR-based aspergillus DNA screening in high-risk patients with and without primary antifungal mould prophylaxis","volume":"22","author":"Springer","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019022811005785800_bib57","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1093\/jac\/dks208","article-title":"Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies","volume":"67","author":"Reinwald","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib58","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0609.2012.01806.x","article-title":"Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples","volume":"89","author":"Reinwald","year":"2012","journal-title":"Eur J Haematol"},{"key":"key\n\t\t\t\t2019022811005785800_bib59","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib60","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/mmy\/myv034","article-title":"Effects of host response and antifungal therapy on serum and BAL levels of galactomannan and (1\u21923)-beta-D-glucan in experimental invasive pulmonary aspergillosis","volume":"53","author":"Petraitiene","year":"2015","journal-title":"Med Mycol"},{"key":"key\n\t\t\t\t2019022811005785800_bib61","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1086\/647935","article-title":"Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases","volume":"49","author":"Maertens","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib62","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib63","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/myc.12434","article-title":"Direct comparison of galactomannan performance in concurrent serum and bronchoalveolar lavage samples in immunocompromised patients at risk for invasive pulmonary aspergillosis","volume":"59","author":"Boch","year":"2016","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019022811005785800_bib64","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1128\/JCM.00467-14","article-title":"Performance of galactomannan, beta-d-glucan, aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis","volume":"52","author":"Hoenigl","year":"2014","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t2019022811005785800_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2018.05.001","article-title":"Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients: Performance of Cytokines, Asp LFD, and Aspergillus PCR in Same Day Blood and Bronchoalveolar Lavage Samples","author":"Heldt","year":"2018","journal-title":"J Infect"},{"key":"key\n\t\t\t\t2019022811005785800_bib66","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/JCM.03189-12","article-title":"Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis","volume":"51","author":"White","year":"2013","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t2019022811005785800_bib67","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jinf.2017.05.014","article-title":"Bronchoalveolar lavage triacetylfusarinine C (TAFC) determination for diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies","volume":"75","author":"Orasch","year":"2017","journal-title":"J Infect"},{"key":"key\n\t\t\t\t2019022811005785800_bib68","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1128\/JCM.02969-15","article-title":"Urine galactomannan-to-creatinine ratio for detection of invasive aspergillosis in patients with hematological malignancies","volume":"54","author":"Reischies","year":"2016","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t2019022811005785800_bib69","doi-asserted-by":"crossref","first-page":"e42736","DOI":"10.1371\/journal.pone.0042736","article-title":"Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis","volume":"7","author":"Dufresne","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019022811005785800_bib70","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3389\/fmicb.2017.02362","article-title":"Evaluation of bronchoalveolar lavage fluid cytokines as biomarkers for invasive pulmonary aspergillosis in at-risk patients","volume":"8","author":"Goncalves","year":"2017","journal-title":"Front Microbiol"},{"key":"key\n\t\t\t\t2019022811005785800_bib71","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022811005785800_bib72","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022811005785800_bib73","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib74","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.leu.2405065","article-title":"Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin","volume":"22","author":"Raad","year":"2008","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019022811005785800_bib75","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1128\/AAC.06015-11","article-title":"Experimental CNS aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, toxicity","volume":"56","author":"Clemons","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib76","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/jps.2600830716","article-title":"Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein","volume":"83","author":"Wasan","year":"1994","journal-title":"J Pharm Sci"},{"key":"key\n\t\t\t\t2019022811005785800_bib77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/JCM.06133-11","article-title":"Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales","volume":"50","author":"Vitale","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t2019022811005785800_bib78","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10156-010-0071-7","article-title":"Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of zygomycetes in a murine lethal infection model","volume":"16","author":"Takemoto","year":"2010","journal-title":"J Infect Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib79","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib80","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases","volume":"42","author":"van Burik JA","year":"2006","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib81","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11046-015-9914-1","article-title":"Successful treatment of primary cutaneous mucormycosis complicating anti-TNF therapy with a combination of surgical debridement and oral posaconazole","volume":"180","author":"Camargo","year":"2015","journal-title":"Mycopathologia"},{"key":"key\n\t\t\t\t2019022811005785800_bib83","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib84","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Hematologica"},{"key":"key\n\t\t\t\t2019022811005785800_bib85","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019022811005785800_bib86","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib87","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00286-10","article-title":"International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole","volume":"54","author":"Lortholary","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib88","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s10096-014-2111-1","article-title":"European confederation of medical mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe","volume":"33","author":"Tortorano","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib89","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.healun.2003.09.033","article-title":"Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient","volume":"23","author":"Herbrecht","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"key\n\t\t\t\t2019022811005785800_bib90","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019022811005785800_bib91","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12465","article-title":"ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others","volume":"20","author":"Tortorano","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019022811005785800_bib92","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/340522","article-title":"Treatment of Scedosporium apiospermum brain abscesses with posaconazole","volume":"34","author":"Mellinghoff","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib93","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10096-002-0877-z","article-title":"Successful control of disseminated scedosporium prolificans infection with a combination of voriconazole and terbinafine","volume":"22","author":"Howden","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/00365540600786564","article-title":"Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine","volume":"39","author":"Bhat","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib95","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1439-0507.2003.00878.x","article-title":"Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery","volume":"46","author":"Gosbell","year":"2003","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2019022811005785800_bib96","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1093\/infdis\/jix130","article-title":"Novel agents and drug targets to meet the challenges of resistant fungi","volume":"216","author":"McCarthy","year":"2017","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019022811005785800_bib97","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: a reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2019022811005785800_bib98","first-page":"2528","article-title":"The investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii","volume":"60","author":"Lockhart","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2019022811005785800_bib99","article-title":"Galactomannan (GM) testing from serum and bronchoalveolar lavage (BAL) for invasive pulmonary aspergillosis (IPA) in high risk patients","author":"Hoenigl","year":"2018","journal-title":"Deutsche Zentralbibliothek f\u00fcr Medizin (ZB MED) \u2013 Informationszentrum Lebenswissenschaften"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/57\/Supplement_2\/S168\/27995364\/myy052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T11:41:20Z","timestamp":1604490080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/57\/Supplement_2\/S168\/5366894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":99,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2019,2,28]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myy052","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,2,28]]}}}